William Hall, MD
Pulmonary Disease · Raleigh, NCNPI 1003031691
Payments from drug & device makers
Across 108 payments — averaging $190.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Intuitive Surgical$3K
- GSK$304
- Merz North America, Inc.$287
- Philips North America LLC$160
- Galvanize Therapeutics, Inc$105
- plus $518 from 16 others
What the payments were for
- Speaking & faculty fees$15,49075%
- Travel & lodging$5813%
- Food & beverage$1,9049%
- Education$2,64113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 23 | $15,936 |
| Intuitive Surgical | 13 | $3,304 |
| GSK | 22 | $304 |
| Merz North America, Inc. | 10 | $287 |
| Philips North America LLC | 10 | $160 |
| Galvanize Therapeutics, Inc | 1 | $105 |
| AstraZeneca | 3 | $95 |
| Insmed, Inc. | 3 | $53 |
| United Therapeutics Corporation | 4 | $47 |
| Inogen, Inc. | 4 | $46 |
| Genentech USA, Inc. | 2 | $39 |
| Covidien LP | 1 | $38 |
| Johnson & Johnson | 2 | $35 |
| CSL Behring | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Electromed, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Infobionic, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$13,090
- Da Vinci Surgical System$2,944
- superDimension$2,400
- ALIYA SYSTEM$105
How this compares
$20,615 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 668 | $559,533 |
| OfevNintedanib Esylate | 30 | $344,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 373 | $278,295 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $149,135 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 272 | $140,558 |
| Spiriva RespimatTiotropium Bromide | 157 | $118,534 |
| Breo ElliptaFluticasone/Vilanterol | 246 | $109,390 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 101 | $80,604 |
| Dupixent PenDupilumab | 11 | $40,999 |
| Incruse ElliptaUmeclidinium Bromide | 76 | $34,769 |
| Spiriva HandihalerTiotropium Bromide | 39 | $30,343 |
| SymbicortBudesonide/Formoterol Fumarate | 90 | $28,426 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 151 | $24,823 |
| Arnuity ElliptaFluticasone Furoate | 79 | $21,547 |
| Advair HfaFluticasone Propion/Salmeterol | 58 | $21,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $304 | $865,7961,341 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $95 | $315,140480 claims |
| Grifols USA, LLCProlastin C | $21 | $149,13513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Raleigh
- Hiren MehtaRaleigh$76K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.